1. Insensitivity to T790M mutation? A pooled analysis of outcomes following osimertinib for the treatment of NSCLC patients harboring uncommon epidermal growth factor receptor mutation
   Shanliang Hu et al, 2022, Frontiers in Pharmacology CrossRef